{"schema_version":"secwatch.filing_event.v1","accession":"0001600620-24-000027","form_type":"8-K","ticker":"AUPH","cik":"0001600620","company_name":"Aurinia Pharmaceuticals Inc.","filed_at":"2024-02-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.764749+00:00","generated_at":"2026-06-05T06:43:04.925377+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Aurinia terminates EVP R&D Volker Knappertz in restructuring","bullets":["Dr. Volker Knappertz, EVP R&D, to be terminated as part of Aurinia's Feb 15 restructuring.","Severance includes 12 months base salary, accrued vacation, performance bonus payout.","Eligible for medical, dental, vision benefits for up to 12 months if release is provided.","Employment agreement terms filed as Exhibit 10.18 to 2023 10-K on Feb 15, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001600620-24-000027","json":"https://secwatch.observer/filing/0001600620-24-000027.json","markdown":"https://secwatch.observer/filing/0001600620-24-000027.md","text":"https://secwatch.observer/filing/0001600620-24-000027.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1600620/000160062024000027/0001600620-24-000027-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1600620/000160062024000027/auph-20240227.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T06:43:04.925377+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f67c5290b2","claim":"Volker Knappertz was terminated as Executive Vice President, Research and Development at Aurinia Pharmaceuticals Inc..","evidence_excerpt":"As part of the restructuring that Aurinia Pharmaceuticals Inc. (Aurinia) announced on February 15, 2024, Aurinia plans to terminate its employment relationship with Dr. Volker Knappertz.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1600620/000160062024000027/0001600620-24-000027-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"terminated"},{"label":"Role","value":"Executive Vice President, Research and Development"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}